T1	ANAT 71 76	semen
#1	AnnotatorNotes T1	C0036614; Seminal fluid; Body Substance | C2756969; Semen; Body Substance
T2	ANAT 79 84	recto
#2	AnnotatorNotes T2	C0034896; Rectum; Body Part, Organ, or Organ Component | C1278926; Entire rectum; Body Part, Organ, or Organ Component
T3	PROC 124 135	tratamiento
#3	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	CHEM 155 165	lamivudina
#4	AnnotatorNotes T4	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T5	CHEM 238 241	RNA
#5	AnnotatorNotes T5	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T6	ANAT 255 260	semen
#6	AnnotatorNotes T6	C0036614; Seminal fluid; Body Substance | C2756969; Semen; Body Substance
T7	ANAT 263 268	recto
#7	AnnotatorNotes T7	C0034896; Rectum; Body Part, Organ, or Organ Component | C1278926; Entire rectum; Body Part, Organ, or Organ Component
T8	ANAT 307 320	tejido rectal
T9	PROC 367 378	tratamiento
#8	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	CHEM 398 408	lamivudina
#9	AnnotatorNotes T10	C0209738; lamivudine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T11	DISO 106 110	VIH+
T12	DISO 486 506	Infección por el VIH
#10	AnnotatorNotes T12	C0019693; HIV Infections; Disease or Syndrome
T13	DISO 554 575	infectados por el VIH
#11	AnnotatorNotes T13	C0458074; Human immunodeficiency virus (HIV) status; Finding
T14	PROC 613 640	tratamiento antirretroviral
#12	AnnotatorNotes T14	C1963724; Antiretroviral therapy; Therapeutic or Preventive Procedure
T15	CHEM 180 191	Bictegravir
#13	AnnotatorNotes T15	C4507568; bictegravir; Immunologic Factor · Organic Chemical · Pharmacologic Substance
T16	CHEM 678 681	RNA
#14	AnnotatorNotes T16	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T17	ANAT 685 691	plasma
#15	AnnotatorNotes T17	C0032105; Plasma; Body Substance
T18	PROC 698 717	visita de screening
#16	AnnotatorNotes T18	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T19	CHEM 196 199	TAF
T20	CHEM 760 763	RNA
#17	AnnotatorNotes T20	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T21	ANAT 767 773	plasma
#18	AnnotatorNotes T21	C0032105; Plasma; Body Substance
T22	PROC 780 799	viista de screening
#19	AnnotatorNotes T22	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T23	PROC 867 886	visita de screening
#20	AnnotatorNotes T23	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T24	PROC 903 927	consentimiento informado
#21	AnnotatorNotes T24	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T25	ANAT 1017 1023	plasma
#22	AnnotatorNotes T25	C0032105; Plasma; Body Substance
T26	CHEM 1031 1034	RNA
#23	AnnotatorNotes T26	C0035668; RNA; Nucleic Acid, Nucleoside, or Nucleotide
T27	PROC 1042 1061	visita de screening
#24	AnnotatorNotes T27	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T28	ANAT 1096 1111	Linfocitos CD4+
#25	AnnotatorNotes T28	C0039215; CD4 Positive T Lymphocytes; Cell
T29	PROC 1084 1111	Recuento de Linfocitos CD4+
T30	PROC 1115 1124	screening
T31	ANAT 1125 1131	CD4+ T
T32	PROC 1138 1157	visita de screening
#27	AnnotatorNotes T32	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T33	DISO 1175 1212	Infección por virus de la Hepatitis B
T34	DISO 1222 1244	Insuficiencia hepática
#28	AnnotatorNotes T34	C0085605; Liver Failure; Disease or Syndrome | C1306571; Hepatic Insufficiency; Pathologic Function
T35	DISO 1277 1286	Neoplasia
#29	AnnotatorNotes T35	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T36	DISO 1298 1319	Infección oportunista
#30	AnnotatorNotes T36	C0029118; Opportunistic Infections; Disease or Syndrome
T37	CHEM 423 434	Bictegravir
#31	AnnotatorNotes T37	C4507568; bictegravir; Immunologic Factor · Organic Chemical · Pharmacologic Substance
T38	CHEM 1357 1380	fármaco antirretroviral
#32	AnnotatorNotes T38	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T39	CHEM 435 438	FTC
#33	AnnotatorNotes T39	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T40	CHEM 439 442	TAF
T41	DISO 246 251	VIH-1
#34	AnnotatorNotes T41	C2363741; HIV-1 infection; Disease or Syndrome
T42	CHEM 1458 1466	fármacos
#35	AnnotatorNotes T42	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T43	DISO 334 338	VIH+
T44	PROC 822 844	recuento de linfocitos
#36	AnnotatorNotes T44	C0200635; Lymphocyte Count measurement; Laboratory Procedure
T45	PROC 1396 1403	Terapia
#37	AnnotatorNotes T45	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T46	DISO 1598 1617	Insuficiencia renal
#38	AnnotatorNotes T46	C0035078; Kidney Failure; Disease or Syndrome | C1565489; Renal Insufficiency; Disease or Syndrome
T47	PROC 1636 1664	filtrado glomerular estimado
#39	AnnotatorNotes T47	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T48	PROC 1717 1728	tratamiento
#40	AnnotatorNotes T48	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T49	PROC 1572 1583	bilirrubina
#41	AnnotatorNotes T49	C0863174; Blood bilirubin measurement; Laboratory Procedure
T50	ANAT 834 844	linfocitos
#42	AnnotatorNotes T50	C0024264; Lymphocyte; Cell
T51	DISO 1424 1435	interacción
#43	AnnotatorNotes T51	C0687133; Drug Interactions; Pathologic Function
T52	CHEM 140 152	dolutegravir
#44	AnnotatorNotes T52	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
T53	DISO 300 303	VIH
#45	AnnotatorNotes T53	C0458074; Human immunodeficiency virus (HIV) status; Finding
T54	CHEM 383 395	dolutegravir
#46	AnnotatorNotes T54	C3253985; dolutegravir; Organic Chemical · Pharmacologic Substance
T55	CHEM 192 195	FTC
#47	AnnotatorNotes T55	C0909839; emtricitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T56	CHEM 625 640	antirretroviral
#48	AnnotatorNotes T56	C0599685; Anti-Retroviral Agents; Pharmacologic Substance
T57	PROC 656 691	Carga viral del VIH-1 RNA en plasma
T58	PROC 738 773	Carga viral del VIH-1 RNA en plasma
T59	PROC 1002 1023	Carga viral en plasma
T60	DISO 1214 1217	HBV
T61	ANAT 1236 1244	hepática
#49	AnnotatorNotes T61	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T62	Observation 1331 1343	Resistencias
#50	AnnotatorNotes T62	C3542449; Drug Resistance Status; Finding
T63	PROC 1548 1551	ALT
#51	AnnotatorNotes T63	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T64	PROC 1555 1558	AST
#52	AnnotatorNotes T64	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T65	ANAT 1612 1617	renal
#53	AnnotatorNotes T65	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T66	DISO 1697 1714	condición clínica
T67	ANAT 850 857	células
#54	AnnotatorNotes T67	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T68	ANAT 1163 1167	céls
T69	PROC 1025 1034	HIV-1 RNA
T70	Date 13 17	2019
T71	LIVB 62 67	virus
#55	AnnotatorNotes T71	C0042776; Virus; Virus
T73	LIVB 88 105	pacientes hombres
#56	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group | C0025266; Male population group; Population Group
T76	LIVB 324 333	pacientes
#57	AnnotatorNotes T76	C0030705; Patients; Patient or Disabled Group
T77	LIVB 347 354	hombres
#58	AnnotatorNotes T77	C0025266; Male population group; Population Group
T78	LIVB 536 543	Hombres
#59	AnnotatorNotes T78	C0025266; Male population group; Population Group
T79	LIVB 546 553	mujeres
#60	AnnotatorNotes T79	C0043210; Woman; Population Group
T80	LIVB 572 575	VIH
#61	AnnotatorNotes T80	C0019682; HIV; Virus
T81	Age 576 585	≥ 18 años
T82	Neg_cue 597 599	No
T83	PROC 1253 1263	Child-Pugh
#62	AnnotatorNotes T83	C3854424; Child-Pugh-Turcotte score; Laboratory Procedure
T86	PHYS 1636 1655	filtrado glomerular
#63	AnnotatorNotes T86	C0232809; Glomerular filtration; Organ or Tissue Function; Laboratory Procedure
T87	LIVB 1756 1768	investigador
#64	AnnotatorNotes T87	C0035173; Research Personnel; Professional or Occupational Group
T89	LIVB 1787 1793	sujeto
#65	AnnotatorNotes T89	C0681850; Study Subject; Group
T92	LIVB 503 506	VIH
#66	AnnotatorNotes T92	C0019682; HIV; Virus
T93	LIVB 662 667	viral
#67	AnnotatorNotes T93	C0042776; Virus; Virus
T94	LIVB 744 749	viral
#68	AnnotatorNotes T94	C0042776; Virus; Virus
T95	LIVB 1008 1013	viral
#69	AnnotatorNotes T95	C0042776; Virus; Virus
T96	LIVB 1189 1194	virus
#70	AnnotatorNotes T96	C0042776; Virus; Virus
T72	LIVB 754 759	VIH-1
#71	AnnotatorNotes T72	C0019704; HIV-1; Virus
T74	LIVB 672 677	VIH-1
#72	AnnotatorNotes T74	C0019704; HIV-1; Virus
T75	LIVB 1025 1030	HIV-1
#73	AnnotatorNotes T75	C0019704; HIV-1; Virus
T84	ANAT 1645 1655	glomerular
#74	AnnotatorNotes T84	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
A1	Assertion T14 Negated
A2	Status T14 History_of
A3	Status T48 History_of
A4	Status T66 History_of
#75	AnnotatorNotes T11	C0458074; Human immunodeficiency virus (HIV) status; Finding
#76	AnnotatorNotes T43	C0458074; Human immunodeficiency virus (HIV) status; Finding
#77	AnnotatorNotes T33	C0019163; Hepatitis B; Disease or Syndrome
#78	AnnotatorNotes T60	C0019163; Hepatitis B; Disease or Syndrome
#79	AnnotatorNotes T8	C0586686; Rectal tissue sample; Tissue
#80	AnnotatorNotes T69	C4764103; HIV-1 RNA Measurement; Laboratory Procedure
#81	AnnotatorNotes T31	C0039215; CD4 Positive T Lymphocytes; Cell
#82	AnnotatorNotes T68	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T85	Spec_cue 1770 1777	pudiera
T88	Observation 1787 1804	sujeto inadecuado
A5	Assertion T88 Speculated
#83	AnnotatorNotes T88	C3242266; patient not eligible; Finding
R1	Speculation Arg1:T85 Arg2:T88	
R2	Experiences Arg1:T89 Arg2:T88	
T90	Neg_cue 1823 1833	incapaz de
T91	Observation 1834 1869	cumplir con una correcta adherencia
A6	Assertion T91 Negated
#84	AnnotatorNotes T91	C2364172; Adherence To Medication Regime; Finding
R3	Negation Arg1:T90 Arg2:T91	
R4	Negation Arg1:T82 Arg2:T14	
R5	Location_of Arg1:T1 Arg2:T71	
R6	Location_of Arg1:T2 Arg2:T71	
R7	Experiences Arg1:T73 Arg2:T11	
R8	Causes Arg1:T71 Arg2:T11	
R9	Experiences Arg1:T73 Arg2:T3	
R10	Used_for Arg1:T52 Arg2:T3	
R11	Combined_with Arg1:T52 Arg2:T4	
R12	Used_for Arg1:T15 Arg2:T3	
R13	Experiences Arg1:T73 Arg2:T15	
R14	Combined_with Arg1:T15 Arg2:T55	
R15	Combined_with Arg1:T55 Arg2:T19	
#86	AnnotatorNotes T40	C3713958; tenofovir alafenamide; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
#87	AnnotatorNotes T19	C3713958; tenofovir alafenamide; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
R16	Combined_with Arg1:T37 Arg2:T39	
R17	Combined_with Arg1:T39 Arg2:T40	
R18	Experiences Arg1:T77 Arg2:T9	
R19	Experiences Arg1:T77 Arg2:T37	
R20	Used_for Arg1:T54 Arg2:T9	
R21	Combined_with Arg1:T54 Arg2:T10	
R22	Experiences Arg1:T77 Arg2:T41	
R23	Experiences Arg1:T77 Arg2:T53	
R24	Experiences Arg1:T77 Arg2:T43	
R25	Experiences Arg1:T76 Arg2:T41	
R26	Experiences Arg1:T76 Arg2:T53	
R27	Experiences Arg1:T76 Arg2:T43	
R28	Experiences Arg1:T76 Arg2:T9	
R29	Experiences Arg1:T76 Arg2:T37	
R30	Location_of Arg1:T6 Arg2:T5	
R31	Location_of Arg1:T7 Arg2:T5	
R32	Causes Arg1:T92 Arg2:T12	
R33	Causes Arg1:T80 Arg2:T13	
R34	Experiences Arg1:T78 Arg2:T13	
R35	Experiences Arg1:T79 Arg2:T13	
R36	Has_Age Arg1:T78 Arg2:T81	
R37	Has_Age Arg1:T79 Arg2:T81	
R38	Used_for Arg1:T56 Arg2:T14	
A7	Status T56 History_of
R39	Location_of Arg1:T17 Arg2:T57	
R40	Location_of Arg1:T21 Arg2:T58	
R41	Overlap Arg1:T57 Arg2:T18	
T99	Result_or_Value 718 734	> 1000 copias/mL
R42	Has_Result_or_Value Arg1:T57 Arg2:T99	
T100	Result_or_Value 800 819	< 500,000 copias/mL
R43	Has_Result_or_Value Arg1:T58 Arg2:T100	
R44	Overlap Arg1:T58 Arg2:T22	
T101	Result_or_Value 845 860	>200 células/µL
R45	Has_Result_or_Value Arg1:T44 Arg2:T101	
R46	Overlap Arg1:T44 Arg2:T23	
R47	Overlap Arg1:T58 Arg2:T23	
R48	Overlap Arg1:T22 Arg2:T44	
#89	AnnotatorNotes T58	C3835525; HIV-1 RNA viral load in plasma by target amplification; Laboratory Procedure (?)
#90	AnnotatorNotes T57	C3835525; HIV-1 RNA viral load in plasma by target amplification; Laboratory Procedure (?)
#91	AnnotatorNotes T59	C3835525; HIV-1 RNA viral load in plasma by target amplification; Laboratory Procedure (?)
T102	CONC 963 972	inclusión
#92	AnnotatorNotes T102	C1512693; Inclusion; Qualitative Concept
R49	Before Arg1:T24 Arg2:T102	
R50	Location_of Arg1:T25 Arg2:T59	
R51	Overlap Arg1:T59 Arg2:T27	
T103	Result_or_Value 1062 1080	>500,000 copias/mL
R52	Has_Result_or_Value Arg1:T59 Arg2:T103	
R53	Has_Result_or_Value Arg1:T69 Arg2:T103	
R54	Overlap Arg1:T69 Arg2:T27	
R55	Overlap Arg1:T29 Arg2:T30	
#93	AnnotatorNotes T29	C1294978; Detection of lymphocytes positive for CD4 antigen; Laboratory Procedure
#26	AnnotatorNotes T30	C1710477; Trial Screening; Research Activity
R56	Overlap Arg1:T29 Arg2:T32	
T104	Result_or_Value 1158 1171	<200 céls./µL
R57	Has_Result_or_Value Arg1:T29 Arg2:T104	
R58	Causes Arg1:T96 Arg2:T33	
R59	Causes Arg1:T96 Arg2:T60	
T105	Result_or_Value 1264 1271	Class C
R60	Has_Result_or_Value Arg1:T83 Arg2:T105	
R61	Location_of Arg1:T61 Arg2:T34	
T106	Quantifier_or_Qualifier 1245 1251	severa
#94	AnnotatorNotes T106	C1547227; Severe - Severity of Illness Code; Intellectual Product
R62	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T106	
T107	Quantifier_or_Qualifier 1320 1326	activa
#95	AnnotatorNotes T107	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R63	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T107	
T108	Quantifier_or_Qualifier 1287 1293	activa
#96	AnnotatorNotes T108	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R64	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T108	
R65	Overlap Arg1:T62 Arg2:T38	
T109	Quantifier_or_Qualifier 1404 1410	activa
#97	AnnotatorNotes T109	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R66	Has_Quantifier_or_Qualifier Arg1:T45 Arg2:T109	
T110	Result_or_Value 1559 1566	≥ 3xLSN
R67	Has_Result_or_Value Arg1:T63 Arg2:T110	
R68	Has_Result_or_Value Arg1:T64 Arg2:T110	
T111	Result_or_Value 1584 1593	≥ 1.5xLSN
R69	Has_Result_or_Value Arg1:T49 Arg2:T111	
R70	Location_of Arg1:T65 Arg2:T46	
R73	Location_of Arg1:T84 Arg2:T86	
R74	Location_of Arg1:T84 Arg2:T47	
T112	Result_or_Value 1665 1676	< 50 mL/min
R75	Has_Result_or_Value Arg1:T47 Arg2:T112	
T113	Observation 1488 1508	valor de laboratorio
#98	AnnotatorNotes T113	C3648370; laboratory tests nonspecific abnormal findings; Finding (?)
T114	Quantifier_or_Qualifier 1535 1542	Grado 4
R76	Has_Quantifier_or_Qualifier Arg1:T113 Arg2:T114	
#99	AnnotatorNotes T66	C4745084; Medical Condition; Finding (?)
R77	Before Arg1:T66 Arg2:T88	
R78	Before Arg1:T48 Arg2:T88	
R79	Experiences Arg1:T89 Arg2:T66	
R80	Experiences Arg1:T89 Arg2:T48	
R81	Before Arg1:T66 Arg2:T91	
R82	Before Arg1:T48 Arg2:T91	
T115	Observation 272 303	cambios en el reservorio de VIH
R83	Location_of Arg1:T8 Arg2:T115	
R84	Experiences Arg1:T76 Arg2:T115	
R87	Causes Arg1:T9 Arg2:T115	
R88	Causes Arg1:T37 Arg2:T115	
T116	CONC 286 296	reservorio
#100	AnnotatorNotes T116	C0012653; Disease Reservoirs; Idea or Concept
R91	Experiences Arg1:T77 Arg2:T115	
T117	Quantifier_or_Qualifier 1344 1353	primarias
#101	AnnotatorNotes T117	C0205225; Primary; Qualitative Concept
R92	Has_Quantifier_or_Qualifier Arg1:T62 Arg2:T117	
R93	Causes Arg1:T42 Arg2:T51	
R94	Causes Arg1:T45 Arg2:T51	
T118	Quantifier_or_Qualifier 1436 1449	significativa
#102	AnnotatorNotes T118	C1546944; Event Seriousness - Significant; Qualitative Concept
R95	Has_Quantifier_or_Qualifier Arg1:T51 Arg2:T118	
A8	Experiencer T73 Patient
A9	Experiencer T76 Patient
A10	Experiencer T77 Patient
A11	Experiencer T79 Patient
A12	Experiencer T78 Patient
A13	Experiencer T87 Other
A14	Experiencer T89 Patient
